BACKGROUND: Placenta accreta spectrum and vasa previa (VP) are congenital disorders of placentation associated with high morbidity and mortality for both mothers and newborns when undiagnosed before delivery. Prenatal diagnosis of these conditions is essential to allow multidisciplinary management and thus improve perinatal outcomes. OBJECTIVE: The objective of the study was to compare perinatal outcome in women with placenta accreta spectrum or vasa previa before and after implementation of targeted scanning protocols. STUDY DESIGN: This retrospective study included 2 nonconcurrent cohorts for each condition before and after implementation of the corresponding protocols (2004e1012 vs 2013e2016 for placenta accreta spectrum and 1988e2007 vs 2008e2016 for vasa previa). Clinical reports of women diagnosed with placenta accreta spectrum and vasa previa during the study periods were reviewed and outcomes were compared. RESULTS: In total, there were 97 cases of placenta accreta spectrum and 51 cases with vasa previa, all confirmed at delivery. In both cohorts, the prenatal detection rate increased after implementation of the scanning protocols (28 of 65 cases [43.1%] vs 31 of 32 cases [96.9%], P < .001, for placenta accreta spectrum and 9 of 18 cases [50%] vs 29 of 33 cases
C ongenital disorders of placental and umbilical cord development include mainly anomalies of placental shape, location and accreta placentation, and velamentous cord insertion and abnormal vasculature. 1 Placental location and the number of umbilical vessels are routinely screened for at the midgestation detailed fetal anatomy scan around the world.
By contrast, placenta accreta spectrum (PAS) and vasa previa (VP), which are associated with high maternal and neonatal morbidity and mortality 2 are not recommended to be screened for by specialist organizations including the American College of Obstetricians and Gynecologists, the American Institute of Ultrasound in Medicine, and Royal College of Obstetricians and Gynaecologists. [3] [4] [5] [6] [7] [8] Although targeted screening of high-risk pregnancies has been discussed, [9] [10] [11] [12] it has not been implemented at national or international level mainly because of limited supporting data but also lack of resources and training programs in many countries. 12 PAS is defined as the abnormal adherence to or invasion of the villous tissue into the myometrium secondary to damage to the endometriummyometrial interface of the uterine wall. 1, 13 Although theoretically any damages to the uterine wall can lead to accreta placentation, the main cause of PAS is the uterine scar of a prior caesarean delivery (CD), the incidence of which has increased exponentially worldwide in the last 2 decades. 2, 12 Adherent and invasive placentation may coexist in the same placental bed and may evolve with advancing gestation. 13 When unsuspected at the time of delivery, attempts to manually remove a placenta accreta typically provoke massive hemorrhage, leading to high maternal morbidity and mortality. 2 The prenatal ultrasound diagnosis of PAS is highly accurate in specialist units, in particular when associated with an anterior placenta previa or low-lying placenta. 12, 14 VP occurs when fetal vessels run through the membranes, cross the internal os of the cervix under the fetal presentation, either to reach a velamentous cord (type I) or to connect the main placenta with a succenturiate or accessory lobe (type II). 1, 2 Being unprotected by the chorionic plate or Wharton's jelly of the umbilical cord, VPs are liable to rupture either in active labor or at amniotomy, which can be rapidly fatal for the fetus. 15 A recent population-based cohort study has shown that 95% of the 58 women diagnosed prenatally with VP had at least 1 risk factor, with VCI (62%) and lowlying placenta (60%) the most prevalent. 16 Twin pregnancies are at higher risks of VCI and VP, and in vitro fertilization (IVF) is an additional risk factor of abnormal cord insertion and VP. 16 The prenatal ultrasound diagnosis of VP using transvaginal sonography and color Doppler imaging is highly accurate and specific. 2, 17 There is increasing evidence that multidisciplinary team (MDT) management of pregnancies with suspected PAS is superior to standard obstetric care, 18, 19 and prenatal diagnosis of VP has been shown to improve the case perinatal survival rates to 95%. 16, 20 We have developed targeted scanning protocols for both PAS and VP including clinical risk factors and ultrasound scoring system for PAS. 21 The aims of the present study was to evaluate the perinatal outcome in women with PAS or VP before and after implementation of targeted scanning protocols.
Materials and Methods
This study included 2 nonconcurrent cohorts of pregnancies complicated by PAS or VP in a single center. In all cases, the diagnosis was confirmed at birth using clinical criteria similar to those proposed by Collins et al 22 for PAS or standard histopathological examination features for both PAS and VP. 1 In cases of PAS, detailed microscopic reports were obtained only in cases who underwent partial myometrial resection or cesarean hysterectomy. Women who did not deliver at our center were excluded from the analysis. This study was approved by our institutional review board (number 238-16).
Targeted scanning protocols were introduced in our antenatal clinics in 2013 for PAS and in 2008 for VP. Before 2013, pregnant patients diagnosed with PAS were managed on a case-by-case basis without MDT care. In 2013, we developed a clinical protocol to scan women with at least 1 previous CD using ultrasound-based scoring system as previously described 21 and to manage them using an MDT approach.
In brief, all women were assessed using a scoring system based on the following: number and size of placental lacunae; obliteration of the demarcation between the uterus and placenta; placental location; color Doppler signals within placental lacunae; hypervascularity of the placentabladder and/or uteroplacental interface zone; and number of previous CDs. Each criteria was assigned 0, 1, or 2 points and the sum of points yielded the final score.
Patients were classified into low ( 5 points), moderate (6e7 points), or high (8e12 points) probability for PAS based on the final score. All pregnant women diagnosed with or suspected of PAS were provided with MDT perinatal care including follow-up until delivery by experienced ultrasonographers and obstetricians and review before delivery by neonatologists, gynecological surgeons, hematologists, and anaesthesiologists.
Preoperative ultrasound mapping of the placental location was performed to assist in determining the optimal approach to abdominal wall entry and uterine incisions to avoid the placenta before delivery of the fetus. Delivery was planned between 35 and 37 weeks, depending on maternal symptoms. When gross placental invasion is evident at surgery, when major bleeding occurs during manual delivery, when the placenta cannot be detached from the uterine wall, or when part of the placenta remains attached, it is common practice in our institute to stop attempting to remove the placenta manually and to place a B-Lynch compressive suture or to perform an emergency cesarean hysterectomy if the bleeding is not controlled.
The presence and severity of placental invasion was determined by the surgeons and the corresponding clinical data were documented in the electronic file of the patient.
Similarly, in 2008, we introduced a targeted ultrasound scanning protocol in pregnancies at risk for VP. 23 The sonographic diagnoses of VP were all conformed by transvaginal sonography combined with color Doppler imaging as previously described. 23 Briefly, the VPs were visualized in gray-scale sonography as parallel or circular echogenic lines within 2 cm from the internal cervical os, while color Doppler showed these structures to be vessels, and pulsed Doppler revealed a fetal arterial or venous waveform.
From 2008, all asymptomatic women presenting with VP were followed up with transvaginal ultrasound for cervical length and VP position every 2 weeks from the time of the first diagnosis of VP until delivery. 17 The timing of delivery was scheduled according to changes in cervical length and/or clinical symptoms (mainly uterine contractions and/or vaginal bleeding), following a course of corticosteroids. When the cervical remains stable with normal fetal development and there are no clinical symptoms, delivery was planned at 35e36 weeks' gestation. 17 Before implementation of the scanning protocols, cases had to be recovered from medical records, whereas all cases after implementation of the protocols were recorded contemporaneously in a database. Data collected included demographics, obstetrical history, surgical findings, intraoperative and postoperative maternal complication, and care. Information collected from neonatal medical records included Apgar score, cord blood gases pH, need for resuscitation and intubation, blood products transfusion, admission to the neonatal intensive care unit, duration of hospital stay, and perinatal mortality. 
Statistical analysis
Statistical analysis was performed by the statistical laboratory at Tel Aviv University using SPSS software (version 24, SPSS Inc, Chicago, IL). Descriptive variables are presented as mean AE SD. Frequencies are presented as percentages.
The Student t test, Pearson c 2 test, Fisher exact test, and the Mann-Whitney rank test were used to compare the selected parameters. Correlations between CD and IVF during the study period were performed using the Pearson coefficient. A value of P < .05 was considered statistically significant.
Results
The search of our database identified 97 pregnancies diagnosed with PAS and 51 with VP. Figure 1 presents the demographics of our obstetric population since 1988. Overall, the number of deliveries has increased during the study period ( Figure 1A ). There was a significant increase in the percentages of both CD (r 2 ¼ 0.96; P < .0001) ( Figure 1B ) and pregnancies resulting from IVF (r 2 ¼ 0.94; P < .0001) ( Figure 1C) . Table 1 and Figure 2 describe and compare the clinical characteristics of the cases diagnosed with PAS before and after the introduction of the scanning protocol. The prenatal detection rate of PAS was significantly higher after the introduction of the protocol (28 of 65 cases, 43.1%, vs 31 of 32 cases, 96.9%, respectively; P < .001).
There were significantly lower estimated intraoperative blood losses (1168 AE 707 vs 1520 AE 845 mL, respectively; P < .01) and related postoperative complications after the introduction of the protocol. The total operative time was around 30 minutes shorter (90.7 AE 46.9 vs 117.1 AE 74.2 minutes, respectively), but this difference did not reach statistical significance. The length of postoperative hospitalization stay was significantly shorter (5.7 AE 2.2 vs 10.9 AE 14.1 days, respectively; P < .05) after the introduction of the protocol.
The clinical characteristics of patients diagnosed with VP before and after implementation of the scanning protocol are presented and compared in ; P < .05) after the introduction of the protocol. At birth, the newborns' initial hemoglobin levels were significantly higher (13.7 AE 3.5 vs 16.5 AE 2.5; P < .05) after the introduction of the targeted protocol. There was only 1 case of perinatal death caused by ruptured VP before the introduction of the protocol.
The false-positive rates for PAS and VP after the introduction of the protocol were 5 of 37 cases, 0.1%, vs 3 of 36 cases, 0.08%, respectively.
Comment

Principal findings of the study
The results of present study indicate that the use of targeted scanning protocols for PAS and VP improves the prenatal diagnosis of both of these congenital disorders and improves perinatal outcome. Accurate prenatal diagnosis enables the involvement of MDT and to plan delivery in centers of excellence with access to blood banks, expert surgeons, and intensive care for both mothers and their newborns. This reduces the risks of perinatal complications mainly perioperative blood loss and postoperative hospitalization for women with PAS and low Apgar scores and umbilical cord pH and higher hemoglobin levels for newborns with VP.
Comparison with existing literature
The prevalence of both PAS and VP have increased over the last decades because of increase in the numbers of CD and easier access to fertility treatment such as IVF in most regions worldwid. 24, 25 Both are associated with a higher incidence of placenta previa or low-lying placenta, and IVF is associated with a higher incidence of VCI and multiple pregnancies. 17, [26] [27] [28] [29] In the present study, we found a similar trends in our population with a progressive increased in the number of singleton pregnancies with a prior CD since 1988 and multiple pregnancies conceived with IVF since.
There is no universal scanning for PAS and VP, and all studies on the prenatal diagnosis of these conditions are from specialist centers. By contrast, there are international screening protocols with standard anatomical views at 11e14 weeks and midgestation ultrasound examinations for all the other fetal organs, and ultrasound diagnosis of PAS and VP is not routinely taught during ultrasound training courses.
Recent population studies have shown that PAS remains undiagnosed before delivery in half to two thirds of cases, 30, 31 whereas in specialist diagnostic units in the United States, approximately a third of cases of PAS remain undiagnosed during pregnancy. 32 In a recent systematic review and meta-analysis, we found that ultrasound imaging is highly sensitive and specific in the prenatal diagnosis of PAS when performed by skilled operators, in particular in women presenting with a low-lying placenta/ previa and a history of prior CD. 12 The pooled performance of ultrasound for the antenatal detection of placenta previa accreta in prospective studies from specialist centers indicates a sensitivity of 97.0% (95% confidence interval [CI], 93.0e99.0); specificity of 97.0% (95% CI, 97.0e98.0), and diagnostic odds ratio of 228.5 (95% CI, 67.2e776.9). 12 The data of the present study indicate that the prenatal detection rate of PAS can be significantly increased by the introduction of a targeted scanning protocol.
VP can be diagnosed prenatally, using combined abdominal and transvaginal ultrasound and color flow mapping, 2 and the training required to make the diagnosis at the midpregnancy scan is simpler than the one required for PAS. The universal screening for VP is an attractive and desirable option to reduce perinatal mortality, 33 but published evidence in support of this approach remains limited to data from specialist centers.
A recent systematic review including 2 prospective and 6 retrospective cohort studies, of which 6 had a poor methodology including a total of 442,633 women, found prenatal detection rates ranging between 53% to 100%. 18 Similar to PAS, the implementation of a targeted scanning protocol improved significantly the prenatal detection rate of VP in our population.
Clinical implications
Regionalization of care for women in a center of excellence with specialist MDT 19, 34 and the use of a standardized management protocol improves maternal outcome in PAS, particularly in invasive cases. 35 The impact on maternal and fetal outcomes of multidisciplinary management approaches is directly linked to the accuracy prenatal diagnosis for both PAS and VP. Because it is unlikely that universal screening will be implemented for both conditions because of cost and lack of trained ultrasonographers to cover the need of a general population, targeted scanning can provide an alternative option to reduce the impact of these conditions on maternal and fetal outcome.
Targeted scanning of PAS should include obstetric risk factors of accreta placentation, mainly previous CD(s). This highlights the need for developing training programs and national guidelines for PAS-targeted scanning protocols. Women with a prior history of CD and presenting with a placenta previa or low-lying placenta have a risk of placenta previa accreta of 4.1% after 1 prior CD and 13.3% after !2 previous CDs and should be reviewed by an experienced sonographer. The prenatal follow-up of a suspected placenta previa accreta is similar that of a noneaccreta placenta previa and will depend mainly on maternal symptoms.
Because appropriate preparation for CD in PAS is crucial for maternal outcomes, we have recently introduced a simple calculator for risk assessment (http://www.assafh.org/Pages/PPCalc/ index.html). Based on the receiveroperating characteristic curve, we found that the most effective US criteria for detection of MAP were the presence Incidence and prenatal detection rate of PAS and VP Incidence (per 1000 deliveries) and prenatal detection rate of PAS and VP during study periods.
PAS, placenta accreta spectrum; VP, vasa previa.
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of the placental lacunae (odds ratio, 3.5), obliteration of the uteroplacental demarcation (odds ratio, 12.4) and placenta previa (odds ratio, 10.5). We are aware that there are also sophisticated rule ways of approaching this matter and our model may undergo modification as additional markers may be found, but the simple rule approach is tempting. 36 The 2014 UK National Screening Committee external review found that a targeted screening of pregnancies with at least 1 high-risk factor could reduce the perinatal loss rate by as many as 150 cases per year. 34 Similar to PAS, the screening for VP could be targeted to women presenting with a low-lying placenta and/or an IVF pregnancy and/ or a multiple pregnancy. 15, 16 The combination of these risks factors could identify 90% of the women at risk of VP, and location of the umbilical cord insertion can be easily evaluated on abdominal ultrasound. There is no consensus on the optimal surveillance strategy in women diagnosed with VP. Data from a decision analysis study comparing 11 strategies for delivery timing in a patient with VP found that an elective cesarean delivery between 34 and 36 weeks balances the risk of premature rupture of the membranes and subsequent fetal hemorrhage and death vs the risks of prematurity. 37 Antenatal hospitalization to allow for closer surveillance for signs of labor in a unit with appropriate neonatal facilities has also been proposed for all pregnancies presenting with VP from 30 to 32 weeks of gestation, but the evidence is weak and based on low-quality evidence. 2, 7 Our recent data suggest that consecutive targeted scanning of women with VP combined with its rate of shortening can assist clinicians in identifying those who are at risk for emergent CD. 38 
Strengths and weaknesses
The main strength of our study is that we have shown for the first time that the implementation of the standardised scanning protocol including clinical risk factors and ultrasound features can identify more than 90% of the cases of PAS or VP prenatally and improve perinatal outcomes for both conditions. The significant increase in the numbers of women with a diagnosis of PAS or VP over time reflects the increase in the main risk factors (ie, CD and IVF pregnancy rates) for these conditions in our study population, highlighting the increasing need for targeted scanning programs.
There are several limitations to the present study. The retrospective design for the historical cohorts (ie, before implementation of the scanning protocols) leads inevitably to missing or incomplete data and an inability to collect all required information. In particular, the mode of conception and history of other prior uterine minor surgical procedures such as curettage or endometrial ablation could not be obtained in all cases. Furthermore, the data derived from a facility-based rather than a population-based registry and whether follow-up was in a specialist center with access to both adult and neonatal intensive care. This can explain the low morbidity associated with VP in the historical cohort.
In cases of PAS, the surgical team was not blinded to the ultrasound findings and the diagnosis of abnormally adherent vs invasive placentation was made by the surgeons during CD. In all cases of abnormal adherence, a conservative management was attempted successfully and no objective histopathological evaluation was obtained.
Conclusion
Although the current literature lacks confirmatory evidence for the potential benefits of universal prenatal screening for both PAS and VP during the second trimester of pregnancy, the diagnosis of these conditions before delivery is essential for the development of local or regional MDT and management protocols. Identifying high-risk groups and targeted scanning is therefore an alternative to universal screening.
Our data suggest that a perinatal strategy including standardized targeted scanning protocols, increasing awareness of health care providers of the main risk factors of PAS and VP, and training in identifying the ultrasound markers of those abnormalities is associated with improved outcome for both PAS and VP. Such an approach should be considered at regional and national levels and evaluated prospectively.
Implications and contributions
The following implications are shown in the investigation: this study was conducted to evaluate the impact of targeted scanning of placenta accreta syndrome and vasa previa on perinatal outcomes; targeted scanning improves maternal and neonatal outcomes for placenta accreta syndrome and vasa previa, respectively; and adding targeted scanning for placenta accreta syndrome and vasa previa to routine antenatal ultrasound examinations is feasible. n
